MannKind elevates Castanga to CEO; 23andMe recruits 5,000 women for study in 9 days
→ Financially-troubled MannKind elevated Michael Castanga from chief commercial officer to CEO. Matthew Pfeffer, the outgoing chief executive, will continue advising the company until the end of July. The company struggled its way through the clinic to end up with an inhaled insulin that diabetics have shunned.
→ Eisai and Charles River Laboratory have extended their preclinical discovery pact for another year. The two companies have been focusing on novel drugs for tropical and neurological diseases. Researchers will begin working with the Medicines for Malaria Venture, which is looking for new compounds to treat drug-resistant malaria.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.